2010 Advances in the Diagnosis and Treatment of the Rheumatic Diseases

Accreditation Statement

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: May 4, 2011
Expiration Date: May 4, 2014

Description

Now in its sixth year, this two‐day symposium has been planned for the providers of care to patients with rheumatic diseases. Given the wide variety of rheumatologic disorders, and an ever‐increasing number of diagnostic procedures and treatment options, it is necessary to provide clinicians with information about strategies for the early diagnosis of these conditions, novel state‐of‐the‐art diagnostic tools, and opportunities to utilize the most effective treatments to ensure optimal patient outcomes.

Target Audience

This activity is intended for rheumatologists, internists, gerontologists, orthopedic surgeons, nurses, nurse practitioners, and other allied health professionals.

Objectives

After attending this activity, the participant will demonstrate the ability to:

  • Recognize the major dermatologic manifestations of the rheumatic diseases
  • Identify how to diagnose and manage osteoarthritis related shoulder, foot, and ankle disorders
  • Appraise current management approaches and controversies in the diagnosis and treatment of lyme disease
  • Discuss new treatment strategies in SLE
  • Introduce quantitative scores by patients and physicians into usual rheumatology care
  • Discuss diagnosis and treatment of common musculoskeletal presentations of lyme disease

Notice About Off-Label Use Presentations

The Johns Hopkins University School of Medicine/ Sixth Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases (EM) may include presentations on drugs or devices, or use of drugs or devices, which have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. The Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.

Copyright Information

All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.

Instructions to obtain a CME Certificate for this activity

To obtain CME Credits for this activity, you must register online at http://www.hopkinscme.edu/CourseDetail.aspx/80024519 . After you have registered and paid the $35 registration fee, please follow the steps given on the website to complete your post-test.
A Certificate of Credits will be given upon passing the post-test with a score of at least 70% or better.  Registrations will not be accepted after May 4, 2014.

Policy on Speaker and Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).  The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.

Full Disclosure Policy Affecting CME Activities

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation.  The presenting faculty reported the following:

John Campbell, MD Grants/Research Support: Synthes
Speaker Bureau: Biomet; Orthohelix
Robin Gawlik, RN Grants/Research Support: Roche
Honorarium: Genentech; UCB
Gerald Lazarus, MD Grants/Research Support: HealthPoint Woundcare
Timothy McAlindon, MD, MPH, MRCP Grants/Research Support: NIH; NIAMS; Cephalon Inc.;
Gelita‐AG; Genetench; Human Genome Sciences; Stryker;
Biotech; Source MDX
Consultant: Nicox; Gelita
Stock Shareholder: Source MDX
Honorarium: GSK; Stryker; Biotech
Patent Royalties: US Patent for conducting clinical trials
(no income anticipated)
Rosalind Ramsey‐Goldman, MD, DrPH Grants/Research Support: Human Genomes Science;
Aspreva; Genentech; Bristol‐Myers Squibb
Consultant: Human Genomes Science
Other Financial or Material Support: Bristol‐Myers Squibb

All other speakers have indicated that they have not received financial support for consultation, research or evaluation or have a financial interest relevant to their presentation.

Note:  Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION

The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:

Rosalind Ramsey‐Goldman, MD, DrPH Only three medications (aspirin, corticosteroids,
hydroxychloroquine) are FDA approved medications for
SLE. All other medications are considered offlabel use.

All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.

Lecture Titles and Objectives

Diagnosing and Managing Steroid Withdrawal Syndrome: An Endocrinologist’s Perspective

Objective: To evaluate steroid induced adrenal insufficiency and how to taper steroids after long-term use.
Robert Salvatori, MD
Associate Professor of Medicine
Division of Endocrinology

Watch Now

Lyme Disease

Objective: To discuss diagnosis and treatment of common musculoskeletal presentations of lyme disease.
Paul Auwaerter, MD, MBA
Associate Professor of Medicine
Division of Infectious Diseases
Chief Medical Officer
Point of Care Information Technology (POC-IT) Center
Clinical Director, Division of Infectious Diseases

Watch Now

Myositis: Recent Updates

Objectives:  To review, in a cased-based format, the various forms of autoimmune myopathies ; To discuss the latest discoveries as they relate to autoimmune myopathies.
Lisa Christopher-Stine, MD, MPH
Assistant Professor of Medicine
Division of Rheumatology
Co-Director, Johns Hopkins Myositis Center

Watch Now

Osteoarthritis Update

Objective:  To review the biologic basis for therapeutic interventions in osteoarthritis.
Timothy McAlindon, MD, MPH, MRCP
Professor of Medicine
Natalie V. Zucker and Milton O. Zucker Professorship in Rheumatology and Immunology
Chief, Division of Rheumatology
Tufts Medical Center
Boston, Massachusetts

Watch Now

Patient Questionnaires as Standard Office Practice: Why and How

Objective: To introduce quantitative scores by patients and physicians into usual rheumatology care.
Theodore Pincus, MD
Clinical Professor of Medicine
Division of Rheumatology
NYU Hospital for Joint Disease
New York, New York

Watch Now

Rheumatoid Arthritis of the Foot & Ankle

Objectives: To identify patterns of disease involvement; To discuss contemporary surgical and non-surgical options for treatment of rheumatoid involvement of the foot and ankle.
John Campbell, MD
Attending Orthopedic Surgeon
Institute for Foot and Ankle Reconstruction
Mercy Medical Center
Baltimore, Maryland

Watch Now

SLE Treatment Update

Objective: To discuss new treatment strategies in SLE.
Rosalind Ramsey-Goldman, MD, DrPH
Solovy Arthritis Research Society
Professor of Medicine
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Watch Now

When Skin Breaks Down: Fudnamentals of Wound Healing for the Rheumatologist

Objective: To diagnose and treat common causes of leg ulcers in rheumatological patients.
Gerald Lazarus, MD
Professor of Dermatology and Medicine
Director, Johns Hopkins Wound Center
Chief, Department of Dermatology,
Johns Hopkins Bayview Medical Center

Watch Now

Nursing Considerations in Rheumatology Medications – Basics to Biologics

Objective: To identify the medications used in treatment of rheumatoid arthritis and discuss side effects and appropriate nursing management.
Robin Gawlik, RN
Infusion Nurse Manager
Arthritis and Rheumatology Associates of Palm Beach
Palm Beach, Florida

Watch Now

Updated: July 9, 2012

Arthritis Center

About Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.